ArticleLupus science & medicine2025
Association of disease-modifying antirheumatic drug selection with hospitalised infection among youth with childhood-onset systemic lupus erythematosus.
Article in Lupus science & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveYouth with childhood-onset SLE (cSLE) have increased risk of serious infection. It is unknown how much of this risk is due to modifiable factors such as choice of immunosuppressant. We aimed to compare hospitalised infection rates in youth with cSLE on different disease-modifying antirheumatic drugs (DMARDs).
methodsWe included youth ≤18 years with cSLE treated from 2009 to 2022 at two centres. Clinical data were extracted from electronic health records and the Paediatric Health Information System. Hospitalised infection frequency was calculated over the first year of treatment in youth included in each DMARD exposure group, stratified by lupus nephritis (LN) status. Cox proportional hazard regression with inverse probability of treatment weighting (IPTW) was used to compare infection rates across DMARD groups, adjusting for corticosteroid dose.
resultsAmong 257 youths with cSLE, 5% had ≥1 hospitalised infection within 1 year of DMARD initiation. 8% of those with LN had ≥1 hospitalised infection compared with 2.5% without LN. In IPTW-adjusted models, children with LN treated with mycophenolate had lower risk of infection compared with those treated with cyclophosphamide (HR 0.12; 95% CI 0.019 to 0.88). Among those without LN, mycophenolate did not differ from azathioprine in infection risk (HR 1.67, 95% CI 0.56 to 4.99). Higher oral corticosteroid dosing (per 1 mg/day of prednisone) was associated with increased risk of infection (HR 1.1, 95% CI 1.05 to 1.15).
conclusionsWe observed higher hospitalised infection rates in children with cSLE and LN compared with those without LN. Among children with LN, those who received cyclophosphamide had more infections than those who received mycophenolate. Methotrexate was associated with lower infection rates than mycophenolate or azathioprine among youth without LN. Higher daily oral steroid dose was significantly associated with increased hospitalised infection risk in youth with non-renal SLE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.